BIND Therapeutics

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

BIND Therapeutics headquartered in United States, North America, operates in the Information Technology, Biotechnology, Health Care, Medical, Clinical Trials sector. The company focuses on Information Technology and has secured $12.9B in funding across 140 round(s). With a team of 51-100 employees, BIND Therapeutics is actively contributing to advancements in Information Technology. Their latest funding round, Series C - BIND Therapeutics, raised $12.4M. Discover more about their projects, partnerships, and impact on our platform.